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Children warrant access to care from clinical pharmacists trained in pediat-
rics. The American College of Clinical Pharmacy Pediatrics Practice and
Research Network (ACCP Pediatrics PRN) released an opinion paper in
2005 with recommendations for improving the quality and quantity of pedi-
atric pharmacy education in colleges of pharmacy, residency programs, and
fellowships. Although progress has been made in increasing the availability
of pediatric residencies, there is still much to be done to meet the direct
care needs of pediatric patients. The purpose of this joint opinion paper is
to outline strategies and recommendations for expanding the quality and
capacity of pediatric clinical pharmacy practitioners by elevating the mini-
mum expectations for pharmacists entering pediatric practice, standardizing
pediatric pharmacy education, expanding the current number of pediatric
clinical pharmacists, and creating an infrastructure for development of pedi-
atric clinical pharmacists and clinical scientists. These recommendations
may be used to provide both a conceptual framework and action items for
schools of pharmacy, health care systems, and policymakers to work
together to increase the quality and quantity of pediatric training, practice,
and research initiatives.




Children* are an important segment of the
population served by pharmacists.1–3 In 2010,
approximately 73.9 million children resided in
the United States, representing 23.9% of the
total population.4 Canadian statistics are similar,
with 7.8 million children, making up 23% of the
population.5 Although most children will spend
the majority of childhood in good health, a sig-
nificant number will require medical care.
According to the 2007 National Survey of Chil-
dren’s Health, over 31 million children, nearly
half of the pediatric population, have at least
*Children are defined in this document as persons aged 21 years
or less.1–3
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one chronic health condition, and 60% of chil-
dren have received a prescription drug during
the previous 12 months.6 The prevalence of
long-term drug use in children is on the rise,
with the treatment of type 2 diabetes, asthma,
hypertension, dyslipidemia, attention-deficit
hyperactivity disorder, and depression account-
ing for the largest increases.7, 8 Children
accounted for approximately 20% of hospital
admissions in 2010, a percentage that has
remained relatively unchanged for the past dec-
ade (see ref. 9, Table 16, frequency distributions
of number of overnight hospital stays during the
past 12 months, by selected characteristics, Uni-
ted States, 2010).9 A recent survey of the pre-
scribing patterns at 52 children’s hospitals found
that on the first day of admission, the median
drug exposure was four distinct drugs in infants
and five in children between 1 and 18 years of
age.10 At 30 days of life, cumulative exposure
had risen to 25 and 42 drugs in infants and
older children, respectively. Moreover, of the
top 15 drugs prescribed for each age group in
the survey (infants, children 1–9 years of age,
and children 10–17 years of age), half of the
drugs were on the Institute for Safe Medication
Practices list of high-alert drugs.11 It is therefore
logical to assume that most pharmacists, regard-
less of setting, will encounter pediatric prescrip-
tions that will necessitate assessing their safety
and effectiveness to ensure optimal care.12
All health care providers, including pharma-
cists, experience significant challenges in provid-
ing optimal care for children. Understanding the
changes in pharmacokinetic and pharmacody-
namic parameters associated with growth and
development, the necessity for dose calculations
based on body weight or body surface area, the
frequent modification of commercially available
dosage forms to make them suitable for adminis-
tration to young patients, and the distinctive
aspects of providing drug education for children
and their caregivers are all essential aspects of
pediatric patient care. Pediatric clinical pharma-
cists have a documented impact on pediatric
patient safety, quality of life, and economic out-
comes dating back to the early 1970s.13–22 A
survey conducted in 1983, over a quarter of a
century ago, reported that 63% of children’s
hospitals had established clinical pharmacy
services.23 As specialized services, such as
pediatrics, have become an expected part of
pharmacy practice, more recent publications
have highlighted the valuable role of pediatric
clinical pharmacists in new settings, ranging
from the pediatric cardiac intensive care unit to
pediatric nephrology and oncology clinics.24–26
These studies demonstrate the value and impact
that highly skilled pediatric clinical pharmacists
can have in all settings where direct patient care
is rendered.
The importance of highly skilled pediatric
clinical pharmacists has also been recognized
outside of the pharmacy profession. The Ameri-
can Academy of Pediatrics has asserted that phar-
macists who are trained, qualified, experienced,
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and/or possess expertise in pediatric pharmaco-
therapy should be collaborating for the benefit
of all pediatric patients in level III neonatal
intensive care units,27 pediatric intensive care
units,28 and in hematology and oncology prac-
tice settings.29 The Joint Commission confers on
pediatric clinical pharmacists a significant role
in pediatric drug safety initiatives. In a 2008
sentinel event alert on preventing pediatric drug
errors, their recommendations included having a
pediatric pharmacy practitioner on all commit-
tees charged with making decisions about drug
management; assigning pharmacists with pediat-
ric expertise to high-risk patient care services
such as neonatal critical care, pediatric critical
care, and pediatric oncology; ensuring that prac-
titioners involved in the care of infants and chil-
dren have comprehensive, specialized training
and; at all times, providing other health care
providers with access to a pharmacist having
pediatric expertise.30
Members of the American College of Clinical
Pharmacy Pediatrics Practice and Research Net-
work (ACCP Pediatrics PRN) and the Pediatric
Pharmacy Advocacy Group (PPAG), referred to
in this paper as the Joint Opinion Group,
strongly affirm that children warrant access to
care from clinical pharmacists trained in pediat-
rics. In 2005, the ACCP Pediatrics PRN released
an opinion paper containing a status report and
recommendations for improving the quality and
quantity of pediatric pharmacy education in col-
leges of pharmacy, residency programs, and fel-
lowships.31 The goal of these recommendations
was to increase the number of students and resi-
dents pursuing a career in pediatrics, as a means
of meeting the patient care needs for pediatric
clinical pharmacists. Since the publication of
that paper, progress has been made with respect
to the number of residencies in pediatric prac-
tice areas; however, there remain continuing and
new challenges in pediatric pharmacy education,
practice, and research. The purpose of this joint
opinion paper is to outline four strategies for
continuing to expand the quality and capacity of
pediatric clinical pharmacists by elevating the
minimum expectations for pharmacists entering
practice to provide pediatric care, standardizing
pediatric pharmacy education, expanding the
current number of pediatric clinical pharmacists,
and creating an infrastructure for development
of pediatric clinical pharmacists and clinical sci-
entists. It is hoped that this paper will provide a
supportive framework for schools of pharmacy,
health care systems, and policymakers considering
expansion of training, practice, or research ini-
tiatives. The ultimate goal of the Joint Opinion
Group is to improve access to pediatric clinical
pharmacy services for all infants, children, and
adolescents, as well as those with continuing
genetic, metabolic, and oncologic needs.
Strategy 1. Elevate the Minimum Expectations
for Pharmacists Entering Practice to Provide
Pediatric Care
Children requiring medical care deserve to
have the services of a health care team made up
of highly trained practitioners, including phar-
macists. All pharmacists should receive a basic
pediatric pharmacotherapy education in order to
meet the needs of children. Knowledge of com-
mon pediatric disease states, pharmacokinetic,
and pharmacodynamic differences related to
growth and maturation, dosing considerations,
and drug error prevention strategies are neces-
sary for appropriate assessment and preparation
of all pediatric prescriptions. Completion of a
postgraduate year 1 (PGY1) program at a pediat-
ric hospital or completion of multiple pediatric
rotations, mentored by an experienced pediatric
clinical pharmacist in a PGY1 program at a
health care system that includes a children’s hos-
pital, should meet the requirements for the posi-
tion of pediatric staff pharmacist or to serve as a
student preceptor at most institutions. To be
considered a pediatric clinical pharmacist and a
residency preceptor, the Joint Opinion Group
recommends a requirement for completion of a
PGY2 pediatric residency or a PGY1 residency
and a minimum of 3 to 4 years of pediatric med-
icine-focused clinical experience, a level of
expertise similar to the published criteria to sit
for the current board certification examinations.
A more uniform approach that provides intra-
professional assurances and clinical credentials,
however, is still needed. In 2009, ACCP released
a white paper suggesting that a board certifica-
tion process would be necessary in potential spe-
cialties such as pediatrics due to the unique
aspects of clinical pharmacy practice in this
patient population.32 The Board of Pharmacy
Specialties (BPS) has recently completed a role
delineation study that supports the development
of a mechanism for credentialing pediatric phar-
macy specialist.33 If BPS certification in pediatric
pharmacy is established, the Joint Opinion Group
recommends that it be an essential credential
for all pharmacists who provide direct pediatric
patient care. In addition, all preceptors for
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pediatric Advanced Pharmacy Practice Experi-
ences (APPEs), PGY1, and PGY2 pediatric rota-
tions and pediatric college faculty should become
board certified in pediatric pharmacy. The Joint
Opinion Group gratefully acknowledges the
ongoing work of the professional organizations
working with BPS to foster support for the certifi-
cation and credentialing of pediatric clinical
pharmacists.
Strategy 2. Standardize Pediatric Pharmacy
Education
Recommended Standards for Doctor of
Pharmacy Curricula
Basic concepts in pediatric patient care should
be part of the standard Doctor of Pharmacy
(PharmD) curriculum.31 Currently, both the
quantity and quality of the pediatric elements
within PharmD curricula are not well defined.
The Accreditation Council for Pharmacy Educa-
tion Accreditation Standards and Guidelines
state that education about “special populations,”
such as pediatrics, must be included, addressing
pathophysiologic and pharmacotherapy altera-
tions, dosage calculation and adjustments, and
drug monitoring for positive or negative out-
comes34; however, these standards fail to address
pediatrics specifically, and do not describe or
delineate the extent and scope to which pediat-
rics should be included in curricula. Thus, a
clear need for additional guidance on the incor-
poration of pediatric topics and standardization
among schools exists.
The Joint Opinion Group strongly recom-
mends more integration of pediatric pharmaco-
therapy into PharmD curricula and believes that
proficiency in pediatric pharmacotherapy is vital
for all pharmacists providing care for children.
This goal may be achieved by collaborating with
adult-based faculty to incorporate the unique
aspects of pediatric pharmacotherapy, as a part of
curricula. An elective course in pediatric pharma-
cotherapy should be available to all interested
student pharmacists to provide in-depth knowl-
edge of treatment for a variety of common pediat-
ric disease states such as hematologic and
oncologic, genetic, and metabolic conditions.
Published descriptions of pediatric pharmacy
elective courses are available to guide schools in
course development, including a recent paper
that documented statistically significant increases
on examination scores in students enrolled in the
elective course compared with their peers who
received only the pediatric content provided in
the required curricula.35–38 Where university
resources are limited, collaboration and sharing
of knowledge among schools of pharmacy,
schools of medicine, and nursing and pediatric
clinical pharmacists in clinical practice, is highly
encouraged. The Joint Opinion Group recom-
mends that school administration and faculties
work with health care systems to create shared or
distance learning opportunities that address pedi-
atric pharmacy-related content and experiences
when these facilities do not exist on campus.
Core pediatric disease topics should be
reinforced during experiential education. All
schools of pharmacy should offer the opportunity
for Introductory Pharmacy Practice Experiences
and APPEs in pediatric patient care settings.
Schools without pediatric pharmacy faculty or
enough pediatric practice sites to meet the needs
of their students should collaborate with pediat-
ric clinical pharmacists at local hospitals or work
with other schools to offer these experiences to
students. To promote the development of future
pediatric practitioners, schools should develop a
mechanism, perhaps through an expansion of
affiliation agreements, to match students inter-
ested in pediatrics to pediatric-specific APPEs,
thereby ensuring the opportunity to explore
pediatric clinical practice and gain experience
before applying for a residency. All students
interested in pediatric clinical pharmacy practice
should also have the opportunity to have a
pediatric pharmacy faculty member as an advisor
or mentor. The Joint Opinion Group recom-
mends the development of a pediatric mentor
program to match pregraduates with faculty or
affiliate faculty with training and/or significant
practice experience in providing direct care to
children. If the number of students interested in
having a mentor in pediatrics exceeds the capac-
ity of the available faculty, the school may wish
to explore collaborative mentoring with a faculty
member matched to the student in other aspects,
who can aid the student in forming a relationship
with a pediatric pharmacist in clinical practice.
Last, the ACCP Pediatrics PRN and PPAG should
partner to develop a database of their members
who would be willing to mentor a student.
Recommended Standards for Faculty Who Teach
Pediatric Pharmacy
Experts who are actively involved in the care
of children should provide pediatric education
at all levels. Pediatric clinical pharmacists are
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responsible for the future growth of pediatric
pharmacy and must be willing and available to
provide education in a variety of didactic and
experiential settings. The Joint Opinion Group
recommends that every school of pharmacy
employ or contract with at least one full-time
pediatric medicine–trained faculty member. This
individual should have completed PGY2 resi-
dency training, pediatric pharmacy fellowship
training, or a PGY1 residency with 3–4 years of
pediatric clinical practice experience. This fac-
ulty member should not only be involved in
clinical practice, but also be a contributor to
pediatric scholarship. In order to meet the needs
of their students, most schools will also need to
engage qualified affiliate or adjunct faculty mem-
bers with expertise in pediatric pharmacotherapy
for didactic and experiential teaching. Affiliate
or adjunct faculty should have attained a similar
level of training and experience as the full-time
faculty member. The Joint Opinion Group rec-
ommends that pediatric faculty strive to collabo-
rate and increase their availability or exposure
through innovative means such as cofunded fac-
ulty, webcasts, podcasts, broadcasted lectures, or
simulations that could be made available to a
broader audience.
Recommended Standards for Residency Training
Programs
As stated in previous publication,39 PGY1 resi-
dency training provides opportunity for phar-
macy graduates to “enhance and broaden their
competencies.” All PGY1 residencies, regardless
of setting, should offer a pediatric rotation. It is
important to provide fundamental pediatric edu-
cation to PGY1 residents, as many will provide
care for children in ambulatory or acute care
settings, such as family medicine clinics, emer-
gency departments, and community hospitals. A
PGY1 pediatric rotation can provide opportuni-
ties for residents to explore and expand their
pediatric experiences. Furthermore, it would
provide residents the foundation to develop the
necessary entry-level pediatric knowledge and
background to practice for a wide variety of
ages, including infants, children, and adoles-
cents. If the institution does not provide pediat-
ric patient care, the residency program director
should collaborate with pediatric clinical phar-
macists at local institutions to provide one or
more rotation sites. Preceptors for resident rota-
tions in pediatric patient care settings should
meet the qualifications outlined above for
preceptors of students, as well as those recom-
mended by the American Society of Health-Sys-
tem Pharmacists (ASHP).40
A PGY2 residency in pediatric pharmacy
should focus on specialized practice to prepare
graduates to assume pediatric clinical pharmacist
practice positions and/or academic appoint-
ments. These programs should meet the stan-
dards set forth in the ASHP Educational
Outcomes, Goals, and Objectives for PGY2 Phar-
macy Residencies in Pediatrics, developed in col-
laboration with PPAG.41 At this level of training,
residents should build on their PGY1 foundation
and become well versed in pediatric patient care
as described in the ASHP standards. They should
be exposed to an array of pediatric patient care
experiences and other pediatric care providers
and specialists, with the goal of having an
expanded knowledge base of drug use in a vari-
ety of clinical settings.
Strategy 3. Expand the Current Number of
Pediatric Clinical Pharmacists
Specific estimates of the number of pediatric
clinical pharmacists needed in direct patient care
are not available in current pharmacy workforce
projections. Members of the Joint Opinion Group
recommend that a national study of pediatric
pharmacy practice be undertaken to establish
projected needs for the pharmacy labor force. An
estimate of the workforce could be based on sev-
eral factors including pediatric health care use,
number of practicing pediatricians, and types of
environments where pediatric pharmacy exper-
tise is needed, such as the care of complex
patients treated in institutional settings. Accord-
ing to the American Medical Association, 13% of
all physicians in the United States are pediatric
health care providers.42 There are approximately
200 accredited pediatric medical residencies and
over 8000 residents in 3-year training programs
for pediatric practice, not including fellowships
for subspecialties.43 Data from the Bureau of
Labor Statistics show that there are approxi-
mately one-third as many pharmacists as physi-
cians; in 2011, there were 272,320 pharmacists
in the United States, compared with 602,830
physicians.44 In contrast to the percentage of
pediatricians among physicians, the percentage
of pharmacists practicing in pediatrics is cur-
rently much smaller. According to the Children’s
Hospital Association (CHA), there are approxi-
mately 2000 pediatric clinical pharmacists and
1700 pharmacy technicians for 17,500 dedicated
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pediatric beds in 101 of their members that
responded to a recent survey.45 Coupled with
ASHP National Survey data that indicate only
42% of pediatric hospital directors may have ade-
quate numbers of trained pediatric pharmacists
to address the direct care needs, the profession’s
capacity to provide adequate professional staffing
for children’s hospitals is clearly inadequate.46
In addition to CHA statistics, there are more
than 175 children’s hospitals and more than
35,000 dedicated inpatient pediatric beds in the
United States, including both free-standing insti-
tutions and those associated with a larger health
care system.43 Despite the growing number of
pediatric health care facilities and beds devoted
to neonatal and pediatric critical care, the 2012
ASHP Residency Directory lists only 28 PGY1
pharmacy practice residencies in children’s hos-
pitals and 35 PGY2 pediatric pharmacy resi-
dency programs or a total of 63 programs.47
These programs provide a total of 69 PGY1 and
43 PGY2 resident positions, respectively. Only
eight children’s hospitals offer both PGY1 and
PGY2 residency training programs. Although
this represents an increase from the 22 pediatric
residency programs cited in the 2005 PRN
paper,31 it is inadequate to meet current needs.
As the next step toward increasing collective
capacity, the Joint Opinion Group recommends
that all children’s hospitals offering PGY1 train-
ing develop PGY2 residency programs. In addi-
tion, all institutions with PGY2 pediatric
programs should make an effort to increase the
number of positions they offer. The group also
recommends that future pharmacy labor projec-
tions include an assessment of human resource
requirements for pharmacy practice specialties,
including pediatrics.
Strategy 4. Create an Infrastructure for
Development of Pediatric Clinical Pharmacists
and Clinical Scientists
In addition to addressing the need for more
clinical pharmacist involvement in education
and patient care, the Joint Opinion Group sup-
ports the growing role of pharmacists in pediat-
ric clinical research. Despite financial incentives
provided through the Pediatric Research Equity
Act and the Best Pharmaceuticals for Children
Act to stimulate research, there are still signifi-
cant gaps in the availability of clinical studies
demonstrating the safety and efficacy of many
drugs routinely used in children.48 Pediatric
clinical pharmacists, pediatric clinical pharma-
cologists, and clinical scientists play a vital role
in alleviating these gaps. A greater emphasis
must be placed on pediatric fellowship training
and increased research activities to prepare suffi-
cient numbers of individuals who can contribute
to pediatric research and maximize the knowl-
edge generated through such research. In addi-
tion, pediatric clinical pharmacists and clinical
scientists need to be more fully integrated into
the national infrastructure for pediatric research.
Protected research time and internal startup
funding may be necessary to enable this to
occur. The Joint Opinion Group recommends
the expansion of participation in national and
international practice-based research networks
and collaborative trials to facilitate interprofes-
sional and translational research, as well as
increased involvement on institutional review
boards and national advisory committees.
Pediatric fellowship training devoted to pedi-
atric clinical pharmacy or pharmacology
research has even larger workforce challenges.
The current ACCP directory of residencies, fel-
lowships, and graduate programs lists only three
pediatric fellowships. The American Board of
Clinical Pharmacology website includes four
clinical pharmacology fellowship programs
located in pediatric institutions. These clinical
pharmacology fellowship programs are typically
open to medical residents and pharmacists who
desire intense clinical pharmacology training
and research experience. The actual number of
pediatric clinical pharmacy and clinical pharma-
cology fellowships is unknown because of the
paucity of advertising and information available
on these programs. The advancement of pediat-
ric research and science requires more high-
quality, fellowship-trained pediatric pharmacists.
The Joint Opinion Group recommends that all
children’s hospitals with active pediatric research
programs and fellowship-trained pediatric clini-
cal pharmacists develop or expand the number
of pediatric fellowships they offer. The group
also recommends the creation of a web reposi-
tory for collecting, storing, and accessing clinical
pharmacy and pharmacology fellowship–related
programmatic information. Lastly, pharmacy
trainees interested in research careers should be
encouraged to consider alternative pathways for
training, such as Doctor of Philosophy (PhD)
clinical scientist programs. For current faculty
and practitioners who wish to expand or opti-
mize their research skills, programs such as the
ACCP Focused Investigator Training or Research
Academy are available.
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Essential Pediatric Research Curriculum in
PharmD and Postgraduate Programs
In 2010, the ACCP Task Force on Research in
the Professional Curriculum made recommenda-
tions for an essential research curriculum to be
included in the professional program leading to
the PharmD degree.49 There are many ways in
which schools of pharmacy can foster specific
interest in pediatric research, most importantly
by incorporating coursework related to develop-
mental pharmacology (pediatric pharmacokinet-
ics, pharmacogenomics, and pharmacodynamics)
in the core therapeutics curriculum and by
increasing exposure to and availability of PhD
programs. With this knowledge, the pediatric
clinical pharmacist will be able to identify gaps
in our current knowledge and develop capabili-
ties for future research. It is recommended that
the essentials of pediatric research be taught by
pediatric and/or research subject matter experts
when possible. These concepts may be addressed
or reinforced in a separate course or a module
of core topics such as research methods or
literature evaluation. In addition, all PharmD
programs should strive to incorporate a require-
ment for completion of a research project, to be
used as the basis to teach translational research.
The opportunity for conducting pediatric
research should be made available to all students
considering a career in this area.50–55
Both PGY1 and PGY2 residency training pro-
grams are required to provide trainees with
research experiences. As with PharmD programs,
all interested pharmacy residents should have
the opportunity to participate in pediatric clini-
cal research. Although core research knowledge
from PharmD and residency experiences is
essential for pediatric pharmacy practice to accu-
rately perform and interpret clinical research,
preparation of the research-focused pediatric
clinical pharmacist, pharmacologist, or PhD
exceeds this level of training.49, 51–54
With an emphasis on scholarship, pediatric
fellowship training programs should provide
advanced learning experiences in study concep-
tualization, design, implementation, analysis,
and dissemination of results. Scholastic activities
should focus on pathophysiology and therapeu-
tics for infants, children, and adolescents, with
special training regarding research issues specific
to this population, such as ethical concerns
related to a vulnerable population, strategies for
obtaining data with noninvasive or minimally
invasive sampling, and methods for assessing
adverse events. Coursework or workshops in
grant writing, research methodology, and biosta-
tistics should be offered as part of preparation
for a pediatric research career. Development of
teaching skills should also be part of the fellow-
ship training program; this includes lecture
preparation, examination of different learning
styles, composition of exam questions, and
course development. Continued clinical practice
through service as a consultant or in the clinic
is also recommended to maintain clinical skills
and establish a link between clinical practice
and the development of new research questions.
As previously stated, several fellowship pro-
grams are currently available for pediatric clinical
pharmacists wishing to pursue a research career,
Table 1. Summary of The Joint Opinion Group Recom-
mendations for Meeting the Pediatric Patient’s Need for a
Clinical Pharmacist
Employers require completion of a PGY2 pediatric
residency, PGY1 residency plus 3–4 yrs of pediatric
experience, or board certification when available, as a
requirement for pediatric clinical pharmacist positions
Faculties consider focused integration of pediatric
pharmacotherapy into PharmD curricula and believe
that proficiency in pediatric pharmacotherapy is vital for
all pharmacists providing care for children
School administration and faculties work with health
care systems to create shared and/or distance learning
opportunities that address pediatric pharmacy-related
content and experiences
A mentoring program be developed at all schools of
pharmacy to match pregraduates with faculty or affiliate
faculty trained in and/or with significant practice
experiences in providing direct care to children
The ACCP Pediatrics PRN and PPAG partner to develop
a database of their members who would be willing to
mentor students
Every school of pharmacy employ or contract with at
least one full-time pediatrics-trained faculty member to
provide pre-graduate instruction
All children’s hospitals that currently offer PGY1 training
develop PGY2 pediatric residency programs and that all
PGY2 programs make an effort to increase the number
of positions they offer
A web repository be created for collecting, storing, and
accessing clinical pharmacy and pharmacology
fellowship-related programmatic information
All children’s hospitals with active pediatric research
programs and fellowship-trained pediatric clinical
pharmacists develop or expand the number of pediatric
fellowships that they offer
All pediatric fellowship training programs voluntarily
undergo a multidisciplinary peer review process
Future pharmacy labor projections include an assessment
of human resource requirements for pharmacy practice
specialties, including pediatric pharmacy
PGY1 = Postgraduate year 1; PGY2 = Postgraduate year 2; ACCP
Pediatrics PRN = American College of Clinical Pharmacy Pediatrics
Practice and Research Network; PPAG = Pediatric Pharmacy Advo-
cacy Group.
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but the number of available programs needs to be
expanded and peer-reviewed. The Joint Opinion
Group recommends that all pediatric fellowship
training programs voluntarily undergo a multidis-
ciplinary peer review process, such as that offered
by ACCP or the American College of Clinical Phar-
macology. This review would help to ensure the
quality of new and existing training programs.55
An increase in the number of fellowship-trained
pediatric clinical pharmacists and clinical scien-
tists will elevate the visibility of pediatric phar-
macy, increase the number of pharmacy-trained
clinical investigators, and provide more opportu-
nities for interdisciplinary synergy to stimulate the
flow of innovative ideas and drug information for
the advancement of pediatric health care.
Conclusions
The Joint Opinion Group believes that a stra-
tegic approach is needed to increase the work-
force and collective capacities of our profession
for providing pediatric clinical pharmacy ser-
vices. The recommendations outlined in this
opinion paper (Table 1) are provided to encour-
age focused collaboration among schools of
pharmacy, health care facilities, and professional
organizations to enrich the quality of health care
and improve access to pediatric clinical pharma-
cist care for all children.
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